These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 21591300)

  • 1. [Hormone therapy of locally advanced cancer of the prostate validated by several randomized trials].
    Mazeron JJ
    Bull Cancer; 2011 Feb; 98(2):93-4. PubMed ID: 21591300
    [No Abstract]   [Full Text] [Related]  

  • 2. [Combination of external irradiation and androgen suppression for prostate cancer: facts and questions].
    Bolla M; Fourneret P; Beneyton V; Tessier A; Jover F; Verry C
    Cancer Radiother; 2010 Oct; 14(6-7):510-4. PubMed ID: 20728391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Recent multicenter study protocols in the USA for patients with metastatic prostatic carcinoma].
    DeAntoni E; Crawford ED
    Urologe A; 1995 Sep; 34(5):382-8. PubMed ID: 7483154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Twenty-five year evolution of medical hormonal therapy for prostate cancer.
    Moul JW
    BJU Int; 2009 Jan; 103(2):145-6. PubMed ID: 19278531
    [No Abstract]   [Full Text] [Related]  

  • 5. Combined hormone therapy and radiation therapy for locally advanced prostate cancer.
    Bolla M; Laramas M;
    Crit Rev Oncol Hematol; 2012 Dec; 84 Suppl 1():e30-4. PubMed ID: 21144766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.
    Sato N; Akakura K; Isaka S; Nakatsu H; Tanaka M; Ito H; Masai M;
    Urology; 2004 Aug; 64(2):341-5. PubMed ID: 15302491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Total androgen blockade].
    Namiki M; Mizokami A
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():193-8. PubMed ID: 12599570
    [No Abstract]   [Full Text] [Related]  

  • 8. Re: Olav Erich Yri, Trine Bjoro and Sophie D. Fossa. Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer. Eur Urol 2006;49:54-58.
    Pitts WR
    Eur Urol; 2007 Mar; 51(3):864. PubMed ID: 16860461
    [No Abstract]   [Full Text] [Related]  

  • 9. Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial.
    Mottet N; Peneau M; Mazeron JJ; Molinie V; Richaud P
    Eur Urol; 2012 Aug; 62(2):213-9. PubMed ID: 22502942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Side-effects of post-treatment biopsies in prostate cancer patients treated with endocrine therapy alone or combined with radical radiotherapy in the Scandinavian Prostate Cancer Group-7 randomized trial.
    Solberg A; Widmark A; Tasdemir I; Ahlgren G; Angelsen A
    Scand J Urol Nephrol; 2011 Sep; 45(4):233-8. PubMed ID: 21452932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant hormone therapy and radical radiotherapy for localized prostate cancer: poorer biochemical outcome using flutamide alone.
    Wilson KS; Ludgate CM; Wilson AG; Alexander AS
    Can J Urol; 2000 Oct; 7(5):1099-103. PubMed ID: 11114872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Letter to the Editor; Re: Wirth MP, Weissbach L, Marx F-J, Heckl W, Jellinghaus W, Riedmiller H, Noack B, Hinke A, Froehner M. Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer. Eur Urol 2004;45:267-70.
    Rocco B; Matei DV; de Cobelli O; Rocco F
    Eur Urol; 2004 Aug; 46(2):272-3; author reply 273. PubMed ID: 15245825
    [No Abstract]   [Full Text] [Related]  

  • 13. Hormone therapy adjuvant to external beam radiotherapy for locally advanced prostate carcinoma: a complication-adjusted number-needed-to-treat analysis.
    Jani AB; Kao J; Hellman S
    Cancer; 2003 Dec; 98(11):2351-61. PubMed ID: 14635069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Residual prostate cancer in patients treated with endocrine therapy with or without radical radiotherapy: a side study of the SPCG-7 randomized trial.
    Solberg A; Haugen OA; Viset T; Bergh A; Tasdemir I; Ahlgren G; Widmark A; Angelsen A
    Int J Radiat Oncol Biol Phys; 2011 May; 80(1):55-61. PubMed ID: 20598453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hormonal treatment alone for locally advanced prostate cancer.
    Mottet N
    BJU Int; 2004 Dec; 94 Suppl 3():14-5. PubMed ID: 15521888
    [No Abstract]   [Full Text] [Related]  

  • 16. Is 6 months of androgen suppression therapy plus radiotherapy of benefit in patients with localized prostate cancer?
    Pollack A; Horwitz EM
    Nat Clin Pract Oncol; 2005 Jan; 2(1):12-3. PubMed ID: 16264846
    [No Abstract]   [Full Text] [Related]  

  • 17. [A posteriori biological demonstration of the concept of hormone-radiotherapy combination in cancer of the prostate].
    Magné N
    Bull Cancer; 2013 May; 100(5):415-6. PubMed ID: 23862197
    [No Abstract]   [Full Text] [Related]  

  • 18. Re: Olav Erich Yri, Trine Bjoro and Sophie D. Fossa. Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer. Eur urol 2006;49:54-8.
    Sharma R; Sundar S
    Eur Urol; 2007 Apr; 51(4):1146. PubMed ID: 17161523
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase 3 HERO Trial Finds Relugolix to Be Superior to Leuprolide in Prostate Cancer.
    Slater H
    Oncology (Williston Park); 2020 Jul; 34(7):252. PubMed ID: 32674208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy.
    Herr HW; O'Sullivan M
    J Urol; 2000 Jun; 163(6):1743-6. PubMed ID: 10799173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.